Osimertinib is a targeted drug of several generations

Osimertinib (Osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) oral drug developed by AstraZeneca Pharmaceuticals. It is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) if the tumor is positive for the T790M mutation for EGFR expression as detected by a U.S. Food and Drug Administration (FDA) approved test and has progressed after treatment with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of NSCLC patients have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations in tumor cells.

ExonDeletions around the LREA motif in the L858R point mutation in exon 19 and exon 21 are associated with treatment response. The development of third-generation EGFR-TKIs, such as osimertinib, is to cope with changes in tumor resistance patterns after treatment and toxic side effects that affect patients' quality of life. Third-generation inhibitors are specific for the gatekeeper T790M mutation, which increases ATP binding activity to EGFR and leads to poor prognosis in advanced disease. Additionally, osimertinibhas been shown to avoid wild-type EGFR during treatment, thereby reducing nonspecific binding and limiting toxicity.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.